US FDA Approves Sotyktu^™ Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis

Bristol Myers Squibb announced that the US FDA approved Sotyktu™ for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.